PreludeDx Presents New Data at AACR Confirming No Significant Radiation Benefit in DCISionRT Low-risk Patients

DCISionRT Demonstrated to Be Superior Predictor of Risk Recurrence and RT Benefit over Traditional Clinpath LAGUNA HILLS, Calif., Sept. 9, 2022 /PRNewswire/-- Prelude Corporation (PreludeDxä), a leader in molecular diagnostics and precision medicine for early-stage breast cancer,...

Click to view original post